Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Swift & Co, historically a global leader in the meatpacking industry, played a foundational role in the early life sciences and pharmaceutical sectors through its pioneering work in organotherapeutics. By utilizing animal by-products, the company became a primary supplier of raw materials for the isolation of life-saving treatments, most notably providing the pig pancreases used by Eli Lilly and the University of Toronto to produce the first commercial insulin in the 1920s. Beyond insulin, the company's pharmaceutical division manufactured various glandular extracts, enzymes like pepsin, and surgical sutures. While the company's core business was food processing, its vertical integration and scientific innovation were critical to the birth of the modern biologics industry. Today, the legacy of Swift & Co continues under the ownership of JBS S.A., though its independent pharmaceutical operations have long since been absorbed or discontinued.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Swift & Co.